

Transtema - Charging for New Verticals

Redeye raises its forecasts and Base Case for Transtema following a strong Q3 report. As Transtema now is a healthy business, management highlights several growth opportunities, which we find attractive.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema - Charging for New Verticals